J&J Not Sweating Remicade Biosimilar Approval
This article was originally published in The Pink Sheet Daily
The company remains comfortable with the growth outlook for pharmaceuticals despite FDA approval of a rival biosimilar to its blockbuster Remicade, the firm said during its first quarter conference call.
You may also be interested in...
The big pharma financial reporting season gets underway on July 19 with Novartis and Johnson & Johnson in the vanguard. Biosimilar threats to immunology and cancer drugs and new product ramp-ups are among the key things to watch for as results are announced.
Pfizer's biosimilar franchise is well on its way to becoming a blockbuster business three years after the company launched its first US biosimilar.
The partners have filed the first-in-class NGF inhibitor at the lower 2.5mg dose for the treatment of osteoarthritis pain, despite the drug’s challenging safety profile.